Eye Disease Articles & Analysis

LKC Technologies is pleased to announce that the Brazilian Health Regulatory Agency (Anvisa) has granted approval of the UTAS® device, making this a significant advancement in the preservation and enhancement of sight for patients in Brazil. LKC is collaborating with Oculus Brasil to provide physicians with broader access to LKC’s UTAS System and RETeval devices. Both are in extensive ...

By LKC Technologies, Inc.

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction ...

By ViGeneron GmbH

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen ...

By ViGeneron GmbH

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on ...

By Regeneron Pharmaceuticals Inc.

LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet delivery technology. LayerBio will present preclinical study results at the Association for Research in ...

By LayerBio, Inc

CORALVILLE, IOWA July 26, 2022 – Digital Diagnostics is proud to announce a partnership with ArchWell Health to bring IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) – including diabetic macular edema (DME) – to ArchWell Health centers across the United States. “ArchWell Health is committed to improving patient outcomes and ...

By Digital Diagnostics Inc.

UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in ...

By UNITY Biotechnology

LONDON – Friday 18 December 2020 – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead ...

By Gyroscope Therapeutics Limited

Dr Peter Widdowson becomes CTO & company moves to Norwich Research Park Norwich, UK, July 29 2020 – Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has appointed experienced gene therapy developer Dr Katie Binley as Chief Scientific Officer. At Oxford Biomedica for over 20 years, she worked on a range of ocular programmes, managing their ...

By Ikarovec

The award will enable Dr Yogesan Kanagasingam, Research Director for the Australian e-Health Research Centre (AEHRC), to spend four months at Stanford University School of Medicine developing and validating a new ‘non-invasive’ system to screen newborn babies. CSIRO Chief Executive, Dr Megan Clark, said Dr Kanagasingam’s work has application across a wide range of areas, ranging from remote, ...

By CSIRO, the Commonwealth Scientific and Industrial Research Organisation

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). ...

By Glaukos Corporation

BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022. Dr. Haishan Jang, Chair and CEO ...

By BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. Dr. Haishan Jang, Chairwoman and CEO of BRIM Biotechnology, ...

By BRIM Biotechnology, Inc.

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) showed improvement in visual acuity through 24 weeks following single dose of UBX1325 Phase 2 clinical studies of UBX1325 currently enrolling patients with DME and wAMD UNITY Biotechnology, Inc. ...

By UNITY Biotechnology

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell ...

By Opsis Therapeutics

Royal DSM, the global Life Sciences and Materials Sciences company, announces today that it has signed an agreement with P&R Group (Italy) to acquire Vitatene S.A.U., based in León (Spain), a producer of natural carotenoids. The acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues ...

By DSM

Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales The collaboration further validates ...

By ViGeneron GmbH

Ace Therapeutics, an integrated service provider for glaucoma research, is proud to announce the release of its proteomic analysis services for glaucoma research. These cutting-edge analysis services are expected to revolutionize the way researchers approach the study of glaucoma, a leading cause of irreversible blindness worldwide. Glaucoma is a group of eye diseases characterized by damage to ...

By Ace Therapeutics

BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). If the FDA has no further comments after the 30-day review period, BRIM will proceed to initiate the Phase 3 clinical trial in December. Based on its ...

By BRIM Biotechnology, Inc.

The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, the naked eye’s powers are limited. That’s where OCT technology comes in handy. OCTs have become a standard of care that every practice ...

By Lombart Instrument, Inc.